Avondale Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Avondale Wealth Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,000	Closed	-$132K	–	117
2024 Q4	$132K	Hold	1,000	–	–	0.08%	57
2024 Q3	$146K	Hold	1,000	–	–	0.09%	53
2024 Q2	$137K	Hold	1,000	–	–	0.09%	58
2024 Q1	$137K	Sell	1,000 -416	-29%	-$56.8K	0.1%	53
2023 Q4	$192K	Sell	1,416 -1,333	-48%	-$163K	0.16%	45
2023 Q3	$336K	Sell	2,749 -416	-13%	-$52.9K	0.3%	33
2023 Q2	$402K	Sell	3,165 -1,832	-37%	-$238K	0.34%	30
2023 Q1	$645K	Hold	4,997	–	–	0.56%	21
2022 Q4	$656K	Hold	4,997	–	–	0.57%	17
2022 Q3	$584K	Buy	4,997 +3,164	+173%	+$393K	0.64%	17
2022 Q2	$216K	Sell	1,833 -1,078	-37%	-$128K	0.25%	34
2022 Q1	$379K	Sell	2,911 -50,835	-95%	-$6.62M	0.45%	26
2021 Q4	$8.2M	Sell	53,746 -1,025	-2%	-$159K	8.3%	5
2021 Q3	$8.86M	Sell	54,771 -322	-0.6%	-$54.2K	8.65%	3
2021 Q2	$9.02M	Sell	55,093 -691	-1%	-$106K	8.43%	3
2021 Q1	$8.4M	Buy	55,784 +3,200	+6%	+$508K	8.27%	4
2020 Q4	$7.97M	Buy	52,584 +4,827	+10%	+$690K	9.23%	4
2020 Q3	$6.47M	Buy	47,757 +1,016	+2%	+$138K	9.78%	5
2020 Q2	$6.39M	Sell	46,741 -2,176	-4%	-$277K	9.08%	5
2020 Q1	$5.27M	Buy	48,917 +5,252	+12%	+$605K	8.32%	6
2019 Q4	$5.26M	Buy	43,665 +40	+0.1%	+$4.46K	7.72%	6
2019 Q3	$4.34M	Sell	43,625 -54,300	-55%	-$5.68M	7.16%	6
2019 Q2	$10.7M	Buy	97,925 +2,393	+3%	+$255K	7.86%	5
2019 Q1	$10.7M	Sell	95,532 -3,557	-4%	-$390K	8.21%	5
2018 Q4	$9.55M	Buy	99,089 +11,267	+13%	+$1.2M	7.93%	4
2018 Q3	$10.7M	Sell	87,822 -30,618	-26%	-$3.61M	10.13%	3
2018 Q2	$13M	Sell	118,440 -10,310	-8%	-$1.1M	10.79%	4
2018 Q1	$13.7M	Buy	128,750 +2,499	+2%	+$277K	11.27%	4
2017 Q4	$13.5M	Buy	+126,251	New	+$13.5M	11.8%	3

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

Avondale Wealth Management's IBB Position: Q1 2025 in Review

Avondale Wealth Management sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 1,000 shares — an estimated $132K sold.

Avondale Wealth Management first reported a position in IBB in Q4 2017 and held it in 29 quarters. The position peaked at $13.7M in Q1 2018. 832 funds tracked by Wall St. Rank hold IBB as of Q1 2025.

Avondale Wealth Management reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
Avondale Wealth Management sold 1,000 iShares Biotechnology ETF shares in Q1 2025, an estimated $132K.
Avondale Wealth Management first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 29 quarters.
Avondale Wealth Management's iShares Biotechnology ETF position peaked at $13.7M in Q1 2018.
832 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.

Based on Avondale Wealth Management's 13F filing for Q1 2025, filed 8 Apr 2025.